conv.

All stories
ScienceQuiet 6d · day 7

Mesothelioma drug disables cancer's antioxidant defense in Phase 1 trial

Experimental treatment targeting PRX3 controlled disease progression in 67% of relapsed patients, reversing decades of failed antioxidant cancer strategies.

newest coverage 5d agosummary written 4d ago2 pieces782 likes & upvotes12 comments NewswiresBluesky

What to know

  • A new mesothelioma drug controlled disease progression in 67% of relapsed patients by blocking PRX3, an antioxidant enzyme tumors use to survive oxidative stress.
  • The approach reverses decades of failed antioxidant cancer strategies—instead of boosting antioxidants, researchers deprive cancer cells of their defenses.
  • The treatment uses thiostrepton, a naturally occurring antibiotic, to disable PRX3 and force hydrogen peroxide accumulation in tumor mitochondria until cells die.
  • Results exceeded standard treatments in a Phase 1 trial; mesothelioma currently has a median survival of 12 months and 10% five-year survival rate.

Brian Cunniff Professor, University of VermontVictoria Gibson Research scientist, University of VermontRS Oncology, LLC Pharmaceutical company

Mesothelioma drug disables cancer's antioxidant defense in Phase 1 trial
sciencedaily.com

How it unfolded 1 development · click the chart to see its coverage articlesposts

Peak 1 piece in two hours at Sep 17, 12 AM; 2 pieces over 7 days (1 article · 1 post) Sep 17, 12 AM — 1 piece · 1 article — Newswires 1Sep 17, 2 AM — quietSep 17, 4 AM — quietSep 17, 6 AM — quietSep 17, 8 AM — quietSep 17, 10 AM — quietSep 17, 12 PM — quietSep 17, 2 PM — quietSep 17, 4 PM — quietSep 17, 6 PM — quietSep 17, 8 PM — quietSep 17, 10 PM — quietSep 18, 12 AM — quietSep 18, 2 AM — 1 piece · 1 post — Bluesky 1Sep 18, 4 AM — quietSep 18, 6 AM — quietSep 18, 8 AM — quietSep 18, 10 AM — quietSep 18, 12 PM — quietSep 18, 2 PM — quietSep 18, 4 PM — quietSep 18, 6 PM — quietSep 18, 8 PM — quietSep 18, 10 PM — quietSep 19, 12 AM — quietSep 19, 2 AM — quietSep 19, 4 AM — quietSep 19, 6 AM — quietSep 19, 8 AM — quietSep 19, 10 AM — quietSep 19, 12 PM — quietSep 19, 2 PM — quietSep 19, 4 PM — quietSep 19, 6 PM — quietSep 19, 8 PM — quietSep 19, 10 PM — quietSep 20, 12 AM — quietSep 20, 2 AM — quietSep 20, 4 AM — quietSep 20, 6 AM — quietSep 20, 8 AM — quietSep 20, 10 AM — quietSep 20, 12 PM — quietSep 20, 2 PM — quietSep 20, 4 PM — quietSep 20, 6 PM — quietSep 20, 8 PM — quietSep 20, 10 PM — quietSep 21, 12 AM — quietSep 21, 2 AM — quietSep 21, 4 AM — quietSep 21, 6 AM — quietSep 21, 8 AM — quietSep 21, 10 AM — quietSep 21, 12 PM — quietSep 21, 2 PM — quietSep 21, 4 PM — quietSep 21, 6 PM — quietSep 21, 8 PM — quietSep 21, 10 PM — quietSep 22, 12 AM — quietSep 22, 2 AM — quietSep 22, 4 AM — quietSep 22, 6 AM — quietSep 22, 8 AM — quietSep 22, 10 AM — quietSep 22, 12 PM — quietSep 22, 2 PM — quietSep 22, 4 PM — quietSep 22, 6 PM — quietSep 22, 8 PM — quietSep 22, 10 PM — quietYesterday, 12 AM — quietYesterday, 2 AM — quietYesterday, 4 AM — quietYesterday, 6 AM — quietYesterday, 8 AM — quietYesterday, 10 AM — quietYesterday, 12 PM — quietYesterday, 2 PM — quietYesterday, 4 PM — quietYesterday, 6 PM — quietYesterday, 8 PM — quietYesterday, 10 PM — quietToday, 12 AM — quiet 1
Sep 18Sep 19Sep 20Sep 21Sep 22yesterdaynow · 2:56 AM ET
  1. 1

    Biologist highlights unconventional mechanism on social media

    A biologist on Bluesky describes the approach as counterintuitive, noting that the strategy uses cancer cells' own defenses against them.

    “Turning the tumor's own protection against it is wild.”
    — biologist077.bsky.social
    1. 1 outlet New mesothelioma drug turns cancer’s own defenses against it

      first by Science Daily, 7d ago

    • biologist077.bsky.social

      New mesothelioma drug disabled cancer's antioxidant defense (PRX3), controlling disease progression in 67% of relapsed patients in a Phase 1 trial. Turning the tumor's own protection against it is wild.

      biologist077.bsky.socialBluesky5d ago782▲view on Bluesky ↗
  2. background

    Phase 1 trial shows 67% disease control in relapsed mesothelioma patients — An RS Oncology-sponsored Phase 1 clinical trial using thiostrepton, a naturally occurring antibiotic that disables PRX3, controlled disease progression in 67% of relapsed mesothelioma patients. Tumors shrank in some patients, the drug was well tolerated, and critically ill trial participants lived longer than patients receiving standard treatments.

  3. background

    UVM researchers publish PRX3-blocking strategy in Nature Communications — Brian Cunniff, Victoria Gibson, and collaborators at the University of Vermont publish research describing an approach to mesothelioma treatment that reverses decades of failed antioxidant cancer strategies by blocking PRX3, an enzyme tumors rely on to survive oxidative stress.